Article Sidebar

Submitted
3 November 2017
Accepted
3 November 2017
Published
3 November 2017
Download
PDF
Statistic
Read Counter : 2106 Download : 1538

Main Article Content

Abstract

Monitoring level of methotrexate is not only aimed at monitoring effectiveness, but also safety aspects of the administration of high-dose methotrexate because the use of high-dose methotrexate is one of the problems associated with toxicity in various organs.  In the use of high-dose methotrexate, measurement of methotrexate is important to identify patients with a high risk of toxicity, particularly nephrotoxicity as well as for dosing guidelines for leucovorin therapy. The aim of this study was to analyze the safety of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. This was a longitudinal, observational prospective study conducted to determine the safety profile of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. Patients who met the inclusion criteria were given high-dose methotrexate according to the 2013 Indonesian ALL Chemotherapy Protocol. Measurement of methotrexate level and kidney function was done 3 times on each cycle of chemotherapy consolidation phase. Measurements were made on the 0, 24 and 48 hours after the first drop of high-dose methotrexate. This study had been reviewed by Ethics Committee of Dr. Soetomo Hospital Surabaya. There were 12 patients who met inclusion criteria and 6 patients among them had finished their chemotherapy consolidation phase completely. There was no significant change in kidney function after the administration of high-dose methotrexate compared to baseline (p>0.05) and there was no significant correlation between serum level of methotrexate versus creatinine clearance. In conclusion, methotrexate was safe to use in children with acute lymphoblastic leukemia.

Keywords

High-dose Methotrexate Kidney Function Acute Lymphoblastic Leukemia Consolidation Phase

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Utomo, F. N., Yulistiani, Y., Zairina, N., & Permono, B. (2017). METHOTREXATE USE IS SAFE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Folia Medica Indonesiana, 53(2), 144–151. https://doi.org/10.20473/fmi.v53i2.6431
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alldredge BK, Corelli RL, Ernst ME, et al (2013). Koda-kimble & young's applied therapeutics: the clinical use of drugs, 10th Ed. Philadelphia, Lippincott Williams & Wilkins
  2. Bleyer WA and Dedrick RL (1978). Clinical pharma-cology of intrathecal methotrexate i pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treatment Reports Vol 61, 703-8
  3. Borsi JD and Moe PJ (1987). A comparative study on pharmacokinetics of methotrexate in a dose range of 0,5 g to 33,6 g/m2 in children with acute lympho-blastic leukemia. Cancer Vol 60, 5-13
  4. Hallworth MJ and Capps NE, 1993. Therapeutic drug monitoring and clinical biochemistry. London, ACB Venture Publications, p 70-73
  5. Hempel L, Misselwitz J, Fleck C, et al (2003). Influence of high dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Medical Pediatric Oncology Vol 40, 348-354
  6. Jacobs SA, Stoller RG, Chabner BA, et al (1976). 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. The Journal of Clinical Investigation Vol 57, 534-538
  7. Kliegman RM, Stanton BF, St. Geme JW, et al (2016). Nelson Textbook of Pediatrics, 20th Ed. Philadelphia, Elsevier, p 2437-244
  8. Lennard L (1999). Therapeutic drug monitoring of antimetabolic cytotoxic drug. British Journal of Clinical Pharmacology Vol 47, 131-143
  9. Odoul F, Le Guellec C, Lamagnere JP, et al (1999). Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic appro-ach. Fundamental Clinical Pharmacology Vol 13, 595-604
  10. Rau T, Erney B, Gores R, et al (2006). High-dose methotrexate in pediatric acute lymphoblastic leuke-mia: Impact of ABCC2 polymorphisms on plasma concentration. Clinical Pharmacology Therapy Vol 80, 468-76
  11. Sahnl V, Choudhury D, Ahmed Z (2009). Chemo-therapy-associated renal dysfunction. Nature Reviews Nephrology Vol 6, 450-462
  12. Xu WQ, Zhang LY, Chen XY, et al (2014). Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Che-motherapy Pharmacology Vol 73, 79-86

Most read articles by the same author(s)

1 2 > >>